Dr. Podell’s laboratory studies the pathogenesis of tuberculosis (TB) to better understand the host immune response to M. tuberculosis infection, known as the granuloma. Our laboratory focuses on identifying immune correlates of protection against M. tuberculosis, the influence of acquired risk factors on the spectrum of TB disease outcomes, and the influence of metabolism on host response to infection. Through this research, we aim to identify targeted responses for vaccine candidates and new approaches to host-directed therapy for improving the prevention and treatment of TB.
People
news and updates view all
A collaborative study, including the CSU Mycobacteria Research Laboratories, provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter regimens.
An interdisciplinary CSU team is advancing a COVID-19 vaccine candidate with additional NIH support, that relies on riboflavin and UV light technology to create inactivated virus.
Associate professors Marcela Henao Tamayo and Brendan Podell will led an interdisciplinary team from the CSU Mycobacteria Research Laboratories to progress a vaccine for tuberculosis.
contact information
Lab: Pathology room 301
Office: Pathology room 308
(970) 491-5746
brendan.podell@colostate.edu